Company profile: PvP Biologics
1.1 - Company Overview
Company description
- Provider of a therapeutic oral enzyme for celiac disease, developing KumaMax to break down the immuno-reactive parts of gluten in the stomach to help reduce symptoms and intestinal damage.
Products and services
- Gluten-Degrading Product Candidate: Enzyme-based, stomach-targeted product candidate designed to break down immuno-reactive gluten fragments in the stomach, aiming to reduce symptoms and intestinal damage in celiac disease
- KumaMax: Oral, enzyme-based therapeutic engineered to break down the immune-reactive parts of gluten in the stomach, reducing symptoms and intestinal damage for celiac disease patients
- Oral Enzyme for Celiac Disease: Enzyme-based, therapeutic product developed to degrade immuno-reactive gluten components in the stomach to lessen the burden of living with celiac disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PvP Biologics
Stromedix
HQ: United States
Website
- Description: Provider of drugs targeting fibrosis, organ failure, and cancer, initially focused on chronic indications, with plans to expand into related settings such as acute organ failure and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stromedix company profile →
Sparrow Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for disorders of corticosteroid excess, including SPI-62, an oral HSD-1 inhibitor designed to reduce intracellular cortisol in conditions like endogenous Cushing’s syndrome and autonomous cortisol secretion, and SPI-47, combining SPI-62 with prednisolone for autoimmune diseases such as polymyalgia rheumatica.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sparrow Pharmaceuticals company profile →
Graviton
HQ: United States
Website
- Description: Provider of novel therapeutics for autoimmune, cancer, certain genetic, fibrotic, and other serious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Graviton company profile →
Amunix
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development, discovering, designing, and developing novel biologics, protein, and peptide therapeutics, with a focus on prodrugs that enable potent immune-activating biotherapeutics for patients with solid tumor cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amunix company profile →
Immunic Therapeutics
HQ: United States
Website
- Description: Provider of selective oral immunology therapies, developing: Vidofludimus Calcium (IMU-838), an investigational oral drug for multiple sclerosis and other chronic inflammatory and autoimmune diseases with neuroprotective, anti-inflammatory and anti-viral effects; IMU-856, a Sirtuin 6–targeting small molecule to restore intestinal barrier and regenerate bowel epithelium for gastrointestinal diseases; and IMU-381, a next-generation GI candidate in preclinical testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PvP Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PvP Biologics
2.2 - Growth funds investing in similar companies to PvP Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PvP Biologics
4.2 - Public trading comparable groups for PvP Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →